Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 81

Sort by

Sort Order Select

Journal Articles

Impact of Immunophenotype on Clinical Disease Characteristics and Outcomes in T-Cell Prolymphocytic Leukemia

Christina Poh, Xueyan Chen, Jenna M. Voutsinas, Edus H. Warren, Mazyar Shadman, Ryan C. Lynch, Brian G. Till, Chaitra S. Ujjani, Mengyang Di, Vikram Raghunathan, Stephen D. Smith, Qian Vicky Wu, Sindhu Cherian, Ajay K. Gopal

Blood (2024) 144 (Supplement 1): 3069.

https://doi.org/10.1182/blood-2024-205892

Published: 2024

Journal Articles

Potential Delayed Immune-Related Adverse Events in Patients Treated with Frontline Pembrolizumab + AVD for Classic Hodgkin Lymphoma

Thomas M Kuczmarski, Chaitra S. Ujjani, Christina Poh, Edus H. Warren, Stephen D. Smith, Mazyar Shadman, Brian G. Till, Vikram Raghunathan, Yolanda D Tseng, Hongyan Du, Jacquelin Vandermeer, Alyssa Kelly, Heather Rasmussen, Jenna M. Voutsinas, Ajay K. Gopal, Ryan C Lynch

Blood (2024) 144 (Supplement 1): 1667.

https://doi.org/10.1182/blood-2024-208412

Published: 2024

Journal Articles

Low Rates of Febrile Neutropenia Despite Frequent Grade 4 Neutropenia in Patients Treated with Pembrolizumab + AVD in Untreated Classic Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 1666.

https://doi.org/10.1182/blood-2024-206601

Published: 2024

Journal Articles

High Rates of Undetectable MRD By Phased-Seq on Interim and End of Treatment Timepoints in Untreated Advanced Stage Chl Treated with Pembrolizumab + AVD

Blood (2024) 144 (Supplement 1): 3051.

https://doi.org/10.1182/blood-2024-206512

Published: 2024

Journal Articles

Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) in Second Line Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma: 5-Year Long Term Follow up

Ryan C. Lynch, Ryan D. Cassaday, Stephen D. Smith, Andrew J. Cowan, Edus H. Warren, Mazyar Shadman, Brian G. Till, Chaitra S. Ujjani, Karolyn Morris, Heather Rasmussen, Jenna M. Voutsinas, Ajay K. Gopal

Blood (2024) 144 (Supplement 1): 3043.

https://doi.org/10.1182/blood-2024-206047

Published: 2024

Journal Articles

Autoimmune Outcomes in Patients with Concurrent Autoimmune Disease Receiving CD19 CAR T-Cell Therapy for Lymphoma

Jennifer J. Huang, Namrata Singh, Mazyar Shadman, Ryan S. Basom, Andrea Kalus, Andrew J Portuguese, Emily C Liang, Natalie Wuliji, Alexandre V. Vinaud Hirayama, Aude G Chapuis, Folashade Otegbeye, Filippo Milano, Ryan D. Cassaday, Ajay K. Gopal, Brian G. Till, Edus H. Warren, Jordan Gauthier, Lawrence Fong, David G. Maloney

Blood (2024) 144 (Supplement 1): 7132.

https://doi.org/10.1182/blood-2024-201809

Published: 2024

Journal Articles

Pralatrexate Is Effective in Cytotoxic Cutaneous T-Cell Lymphomas

Christina Poh, Jenna M. Voutsinas, Ivan Huang, Edus H. Warren, Caitlin A. Crimp, Mazyar Shadman, Ryan C. Lynch, Brian G. Till, Chaitra S. Ujjani, Mengyang Di, Vikram Raghunathan, Stephen D. Smith, Qian Vicky Wu, Michi M. Shinohara, Ajay K. Gopal

Blood (2024) 144 (Supplement 1): 1684.

https://doi.org/10.1182/blood-2024-194018

Published: 2024

Journal Articles

Quality of Life during Survivorship Following Autologous Stem Cell Transplant for Mantle Cell Lymphoma

Mengyang Di, Carrie I Ho, Stephen D. Smith, Mazyar Shadman, Chaitra S. Ujjani, Ryan C. Lynch, Christina Poh, Vikram Raghunathan, Brian G. Till, Edus H. Warren, Ajay K. Gopal, Stephanie J. Lee

Blood (2024) 144 (Supplement 1): 5116.

https://doi.org/10.1182/blood-2024-201827

Published: 2024

Journal Articles

A Phase 1 Study of Subcutaneous Rituximab Hyaluronidase Combined with Local Standard-of-Care Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma in Uganda

Henry Ddugnu, Kelvin Mubiru, Scott V Adams, Jacqueline Asea, Joyce Kambugu, Rosemary Namagembe, Prossy Namuli, Jackson Orem, Camille Puronen, Thomas S. Uldrick, Edus H Warren, Manoj P Menon

Blood (2023) 142 (Supplement 1): 4467.

https://doi.org/10.1182/blood-2023-189875

Published: 2023

Journal Articles

Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis

Christina Poh, Victor A Chow, Ryan C Lynch, Chaitra S Ujjani, Mazyar Shadman, Brian G Till, Vikram Raghunathan, Edus H Warren, Jordan Gauthier, Stephen D Smith, Taran Gujral, Chihiro Morishima, Qian Wu, Jenna M Voutsinas, Amy Sperling, Joshua Dizon, David G Maloney, Ajay K Gopal

Blood (2023) 142 (Supplement 1): 2129.

https://doi.org/10.1182/blood-2023-183034

Published: 2023

Journal Articles

Durable Remissions in Advanced Stage and Molecularly High Risk Untreated Classic Hodgkin Lymphoma with Pembrolizumab + AVD

Blood (2023) 142 (Supplement 1): 4429.

https://doi.org/10.1182/blood-2023-179547

Published: 2023

Journal Articles

Brentuximab Vedotin in Combination with Nivolumab in CD30+ Malignancies Refractory to Brentuximab Vedotin

Christina Poh, Ryan C Lynch, Edus H Warren, Chaitra S Ujjani, Stephen D Smith, Michi M Shinohara, Jonathan R Fromm, Xinyi Fan, Jenna M Voutsinas, Qian Wu, Laura Naylor, Heather Rasmussen, Ajay K Gopal

Blood (2023) 142 (Supplement 1): 3060.

https://doi.org/10.1182/blood-2023-178279

Published: 2023

Journal Articles

Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma

Blood (2023) 141 (21): 2576–2586.

https://doi.org/10.1182/blood.2022019254

Published: 2023

Includes: Supplemental data

Journal Articles

The Impact of B-Cell-Directed Therapy on Sars-Cov-2 Vaccine Efficacy in CLL: 1-Year Follow up

Chaitra S. Ujjani, Christina Poh, Brian Tu, Sydney Lee, Stacy Selke, Haiying Zhu, Mazyar Shadman, Ryan C. Lynch, Meei-Li W Huang, Ajay K. Gopal, Edus H. Warren, Brian G. Till, Stephen D Smith, Amy Sperling, Joshua A. Hill, Philip Stevenson, Leslie Nielsen, Ted A. Gooley, Alexander L Greninger

Blood (2022) 140 (Supplement 1): 13222–13224.

https://doi.org/10.1182/blood-2022-170154

Published: 2022

Journal Articles

Circulating Tumor DNA in Untreated Classical Hodgkin Lymphoma Patients Treated with Pembrolizumab and Chemotherapy: Dynamic Response Assessment and Correlation with Baseline Metabolic Tumor Volume

Blood (2022) 140 (Supplement 1): 6547–6549.

https://doi.org/10.1182/blood-2022-160234

Published: 2022

Journal Articles

Clinical Outcome and Treatment-Related Mortality in Patients with Acute Myeloid Leukemia Treated at the Uganda Cancer Institute

Clement Dove Okello, Soheil Meshinchi, Katherine Tarlock, Edus H. Warren, Andrea M.H. Towlerton, Henry Ddungu, Yusuf Mulumba, Fadhil Geriga, Jackson Orem, Joyce K. Balagadde

Blood (2022) 140 (Supplement 1): 8940–8941.

https://doi.org/10.1182/blood-2022-165982

Published: 2022

Journal Articles

Safety and Efficacy of Third Generation CD20 Targeted CAR-T (MB-106) for Treatment of Relapsed/Refractory B-NHL and CLL

Blood (2021) 138 (Supplement 1): 3872.

https://doi.org/10.1182/blood-2021-149181

Published: 2021

Journal Articles

Peripheral Blood Single-Cell Genotyping and Phenotyping in Multiple Myeloma Reveals Shared Mutations across Multiple Hematopoietic Cell Lineages

David G. Coffey, Aditi Agrawal, Maurizio Morri, Edus H. Warren, Robert Durruthy-Durruthy, Marc Arribas-Layton, Yue Wang, Norma F. Neff

Blood (2021) 138 (Supplement 1): 724.

https://doi.org/10.1182/blood-2021-154531

Published: 2021

Journal Articles

Oral Ixazomib in Untreated Follicular Lymphoma Permits COVID-19 Vaccine Response and Its Efficacy Is Associated with Clinical Factors and Gene Expression Signatures

Solomon A. Graf, Ryan C. Lynch, Chaitra S. Ujjani, Ted A Gooley, David G. Coffey, Andrew J. Cowan, Stephen D. Smith, Mazyar Shadman, Edus H. Warren, Edward Libby, Colin D. Godwin, Alexander L Greninger, Jonathan R. Fromm, Ajay K Gopal

Blood (2021) 138 (Supplement 1): 1363.

https://doi.org/10.1182/blood-2021-153168

Published: 2021

Journal Articles

Normalization of the Immune Microenvironment during Lenalidomide Maintenance Is Associated with Sustained MRD Negativity in Patients with Multiple Myeloma

David G. Coffey, Francesco Maura, Edgar Gonzalez-Kozlova, Javier Diaz-Mejia3, Ping Luo, Yong Zhang, Yuexin Xu, Edus H. Warren, Eric L Smith, Hearn Jay Cho, Alexander Lesokhin, Benjamin Diamond, Dickran Kazandjian, Trevor J. Pugh, Damian J. Green, Sacha Gnjatic, Ola Landgren

Blood (2021) 138 (Supplement 1): 329.

https://doi.org/10.1182/blood-2021-154506

Published: 2021

NARROW

Impact of Immunophenotype on Clinical Disease Characteristics and Outcomes in T-Cell Prolymphocytic Leukemia

Potential Delayed Immune-Related Adverse Events in Patients Treated with Frontline Pembrolizumab + AVD for Classic Hodgkin Lymphoma

Low Rates of Febrile Neutropenia Despite Frequent Grade 4 Neutropenia in Patients Treated with Pembrolizumab + AVD in Untreated Classic Hodgkin Lymphoma

High Rates of Undetectable MRD By Phased-Seq on Interim and End of Treatment Timepoints in Untreated Advanced Stage Chl Treated with Pembrolizumab + AVD

Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) in Second Line Treatment of Relapsed/Refractory Classical Hodgkin Lymphoma: 5-Year Long Term Follow up

Autoimmune Outcomes in Patients with Concurrent Autoimmune Disease Receiving CD19 CAR T-Cell Therapy for Lymphoma

Pralatrexate Is Effective in Cytotoxic Cutaneous T-Cell Lymphomas

Quality of Life during Survivorship Following Autologous Stem Cell Transplant for Mantle Cell Lymphoma

A Phase 1 Study of Subcutaneous Rituximab Hyaluronidase Combined with Local Standard-of-Care Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma in Uganda

Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory B-Cell Lymphoma: A Phase I/II Study of Safety, Efficacy and Immune Correlative Analysis

Durable Remissions in Advanced Stage and Molecularly High Risk Untreated Classic Hodgkin Lymphoma with Pembrolizumab + AVD

Brentuximab Vedotin in Combination with Nivolumab in CD30+ Malignancies Refractory to Brentuximab Vedotin

Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma

The Impact of B-Cell-Directed Therapy on Sars-Cov-2 Vaccine Efficacy in CLL: 1-Year Follow up

Circulating Tumor DNA in Untreated Classical Hodgkin Lymphoma Patients Treated with Pembrolizumab and Chemotherapy: Dynamic Response Assessment and Correlation with Baseline Metabolic Tumor Volume

Clinical Outcome and Treatment-Related Mortality in Patients with Acute Myeloid Leukemia Treated at the Uganda Cancer Institute

Safety and Efficacy of Third Generation CD20 Targeted CAR-T (MB-106) for Treatment of Relapsed/Refractory B-NHL and CLL

Peripheral Blood Single-Cell Genotyping and Phenotyping in Multiple Myeloma Reveals Shared Mutations across Multiple Hematopoietic Cell Lineages

Oral Ixazomib in Untreated Follicular Lymphoma Permits COVID-19 Vaccine Response and Its Efficacy Is Associated with Clinical Factors and Gene Expression Signatures

Normalization of the Immune Microenvironment during Lenalidomide Maintenance Is Associated with Sustained MRD Negativity in Patients with Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only